ADMA Biologics (ADMA) vs Disc Medicine (IRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Disc Medicine (IRON) has outperformed ADMA Biologics (ADMA) over the past year, losing 9.9% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with -45.2% for IRON. Disc Medicine is the larger company by market cap ($2.35 billion vs $2.27 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | IRON |
|---|---|---|
| Share price | $10.14 | $61.18 |
| Market cap | $2.27B | $2.35B |
| 1-day change | -0.39% | -0.76% |
| YTD return | -44.41% | -22.96% |
| 1-year return | -27.52% | -9.88% |
| 5-year return | +821.82% | -45.18% |
| P/E ratio (TTM) | 14.49 | — |
| Forward P/E | 10.75 | — |
| EPS (TTM) | $0.70 | $-6.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $99.50 |
| 52-week low | $7.21 | $40.00 |
| Distance from 52-week high | -50.44% | -38.51% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +67.65% | +68.63% |
| Average volume | 2.63M | 461.14K |
| Shares outstanding | 223.98M | 38.39M |
| Employees | 640 | 165 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRON has outperformed ADMA by 17.6 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
ADMA vs IRON FAQ
Which is bigger, ADMA Biologics or Disc Medicine?
Disc Medicine (IRON) is larger, with a market capitalization of $2.35B compared with $2.27B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or IRON?
IRON returned -9.88% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Disc Medicine in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ADMA Biologics and Biotechnology: Pharmaceutical Preparations for Disc Medicine.